Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
Maxim Group analyst Michael Okunewitch initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $35.
Maxim Group analyst Michael Okunewitch initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $35.